Cancer Vaccines Market Anticipates Impressive Growth Trajectory at a CAGR of 36% During the Forecast Period (2026-2036) | DelveInsight

DelveInsight forecasts a 36% CAGR for the cancer therapeutic vaccines market through 2036, from an estimated $335 million across the U.S., EU4, UK and Japan in 2025; the U.S. represented 87% of the 7MM market. Growth is supported by expanding personalized neoantigen and mRNA vaccine pipelines, including Merck and Moderna's intismeran autogene, which reported positive Phase III melanoma results in August 2026. Regulatory momentum includes FDA accelerated approval of Replimune's TUDRIQEV plus nivolumab for advanced melanoma, though clinical risk remains as IO Biotech's Phase III PFS endpoint for IO102-IO103 did not achieve statistical significance.

Analysis

The investable read-through is not the broad "cancer-vaccine" TAM, but the transfer of value toward platforms that can convert immune priming into durable recurrence reduction while fitting oncology workflow. MRNA/MRK have the clearest opportunity to establish a premium adjuvant-treatment franchise, but MRNA carries disproportionately more upside because oncology optionality can diversify its post-COVID revenue base; MRK's incremental economics are diluted by its much larger checkpoint-inhibitor franchise. The key gating variable over the next 6-18 months is whether individualized manufacturing turnaround, treatment completion rates, and reimbursement support scalable gross margins—not antigen-selection claims alone.

This creates a competitive headwind for single-asset vaccine microcaps whose studies rely on response-rate or immunogenicity signals in metastatic disease. In particular, negative or equivocal randomized data in melanoma should raise the required efficacy bar for IO Biotech and similarly positioned developers, while REPL's commercial execution becomes the more relevant differentiator after regulatory validation: referral-center adoption, combination persistence, and payer friction will determine whether its valuation can sustain beyond an approval-driven move. CADL's prostate program is potentially differentiated because a localized-disease setting can support clearer endpoints and less complex personalized manufacturing, but it remains a regulatory and launch-execution binary rather than a sector read-through.

Consensus may over-extrapolate a high long-term growth forecast to near-term revenue. Combination regimens can expand the treated population yet also concentrate bargaining power with PD-1 owners, compressing vaccine net pricing and making smaller developers dependent on partners. Conversely, success in earlier-stage, minimal-residual-disease settings could be underappreciated: recurrence prevention supports longer treatment duration and higher willingness to pay, while reducing the addressable pool for later-line therapies. Watch for disclosed turnaround time, discontinuation rates, and payer coverage language; failure to demonstrate commercially workable delivery would reverse the platform premium even with positive efficacy.

Key Decisions for Investors

• Maintain an overweight MRNA versus BNTX over 6-12 months, preferably as a paired long MRNA/short BNTX position sized beta-neutral. The catalyst path is additional melanoma/NSCLC execution and oncology revenue visibility; thesis fails if individualized-product turnaround or treatment completion undermines commercial scalability, or if BNTX produces comparable late-stage efficacy with superior manufacturing economics.
• Use MRK as the lower-volatility expression of combination-therapy adoption over 3-9 months, but do not add solely on sector publicity. Require disclosure of economics, treatment duration, and incremental KEYTRUDA demand before underwriting material EPS accretion; a weak launch would likely be immaterial to MRK but would impair the narrative premium in MRNA.
• Treat CADL as an event-driven watch item into its anticipated regulatory submission rather than a core long. Initiate only after confirming filing acceptance, label scope, manufacturing readiness, and cash runway; a defined-risk call spread is preferable to common equity if listed options are sufficiently liquid, given binary approval and commercialization risk.
• Avoid chasing REPL after regulatory validation; reassess at the first two quarterly launch updates. Consider a tactical long only if early demand and gross-to-net trends exceed expectations, while a short becomes attractive if uptake is constrained by administration capacity or reimbursement and the stock still prices a broad melanoma-platform expansion.
• Screen long/short opportunities within vaccine microcaps after each randomized readout: favor companies with registrational endpoints in earlier-stage disease and funded launch paths; avoid firms reliant on exploratory survival subsets or future financing. For GLSI, SLS, GNLX, and OSTX, cash runway and confirmatory-trial design are more important than category enthusiasm over the next 1-3 months.